15450-69-8

Basic information

• Product Name: 1,2,5,6,7,8-HEXAHYDROQUINOLINE-2,5-DIONE
• Synonyms: 1,2,5,6,7,8-HEXAHYDROQUINOLINE-2,5-DIONE;IFLAB-BB F0797-0073;1,2,5,6,7,8-HEXAHYDROQINOLINE-2,5-DIONE;2-HYDROXY-7,8-DIHYDRO-6H-QUINOLIN-5-ONE;7,8-DIHYDROQUINOLINE-2,5(1H,6H) -DIONE;7,8-dihydroquinolin;7,8-Dihydro-1H,6H-quinoline-2,5-dione;2-hydroxy-5,6,7,8-tetrahydroquinolin-5-one
• CAS NO: 15450-69-8
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.17
• Product Categories: pharmacetical
• Mol File: 15450-69-8.mol
• Article Data: 20

Chemical Properties

• Melting Point: 294 °C(Solv: ethanol (64-17-5))
• Boiling Point: 412.342 °C at 760 mmHg
• Flash Point: 200.084 °C
• Appearance: /
• Density: 1.271 g/cm³
• Vapor Pressure: 5.22E-07mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: 2-8°C
• PKA: 10.75±0.20(Predicted)
• CAS DataBase Reference: 1,2,5,6,7,8-HEXAHYDROQUINOLINE-2,5-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,5,6,7,8-HEXAHYDROQUINOLINE-2,5-DIONE(15450-69-8)
• EPA Substance Registry System: 1,2,5,6,7,8-HEXAHYDROQUINOLINE-2,5-DIONE(15450-69-8)

Safety Data

• Hazardous Substances Data: 15450-69-8(Hazardous Substances Data)

Usage

Uses

2-Hydroxy-7,8-dihydroquinolin-5(6H)-one is a useful research chemical.

InChI:InChI=1/C9H9NO2/c11-8-3-1-2-7-6(8)4-5-9(12)10-7/h4-5H,1-3H2,(H,10,12)

Upstream product

• 5220-49-5 3-amino-cyclohex-2-enone 
• 504-02-9 1,3-cylohexanedione 
• 292638-85-8 acrylic acid methyl ester 
• 554-12-1 propanoic acid methyl ester 
• 623-47-2 propynoic acid ethyl ester 
• 84548-18-5 1,2,5,6,7,8-Hexahydro-2,5-dioxo-3-quinolinecarboxamide 
• 106551-67-1 2,5-dioxo-1,2,5,6,7,8-hexahydro-quinoline-3-carbonitrile 
• 85302-07-4 2-(dimethylaminomethylene)cyclohexane-1,3-dione 
• 114920-68-2 2-(γ,γ-bis-N,N-dimethylaminopropylidene)cyclohexane-1,3-dione 
• 36873-28-6 2-carbethoxymethyl-4,4,6-trimethyltetrahydro-(2H)-1,3-oxazine 
• 922-67-8 propynoic acid methyl ester 
• 143261-89-6 2,2-dimethyl-8,9-dihydro-1,3-dioxino<4,5-b>quinoline-4,6-dione 
• 106551-76-2 1,2,5,6,7,8-Hexahydro-2,5-dioxo-3-quinolinecarboxylic acid 
• 127040-30-6 5-oxo-5,6,7,8-tetrahydrocoumarin 

Downstream Products

• 143233-00-5 5,6,7,8-tetrahydro-5-oxo-1-(2-phenylethyl)-2(1H)-quinolinone 
• 1241496-36-5 [(2S,4R)-2-cyclohexyl-4-phenylpiperidin-1-yl][(3R,4S)-2'-methyl-7',8'-dihydro-6'H-spiro[pyrrolidine-3,5'-quinolin]-4-yl]methanone 
• 1355612-02-0 C₂₂H₂₅ClN₂O₂ 
• 124467-36-3 2-chloro-7,8-dihydro-6H-quinolin-5-one 
• 127040-31-7 N-benzyl-5-oxo-5,6,7,8-tetrahydrocarbostyril 
• 57311-38-3 2-Methoxy-5-oxo-5,6,7,8-tetrahydrochinolin 

Relevant articles and documents

Carbon transfer reactions of functionalized oxazolidines and their open chain enamine tautomers to enamine nucleophiles. A facile synthesis of substituted pyridines and ring annulated derivatives

Oxazolidines substituted at C-2 with -CH2-EW(-CO-, etc.) and capable of existing as ring-chain (enamine) tautomers react with cyclic, acyclic and heterocyclic enamine derivatives in a 1:1 stoi-chiometric manner to provide a versatile synthesis of substituted pyridines and their ring annulated derivatives.

SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF

Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

Preparation method of 2-chloro-7, 8-dihydro-6H-quinolin-5-ketone

The invention relates to a preparation method of 2-chloro-7, 8-dihydro-6H-quinolin-5-ketone. 2-chloro-7, 8-dihydro-6H-quinolin-5-ketone comprises preparation components of a component as shown in thedescription, anhydrous ethanol, anhydrous ammonium acetate, anhydrous sodium carbonate, methyl acrylate, DMF, acetonitrile, phosphorus oxychloride and ethyl acetate, and by adopting the preparation method, the existing situation of g-class production is overcome, so that the technical level reaches the industry leading position. Furthermore, the optimized process enables the order batch output ofa project to reach 15 kg, the product quality is improved obviously, the product purity reaches 99.5%, single impurities are lower than 0.1%, and heavy metal, burning residues and residual solvents meet the standards of pharmacopoeia. Technically, the process is optimized, therefore the overall yield of the process is increased by 30%, and the discharge of three wastes (waste water, waste gas andwaste residues) is reduced through the recovery of the solvents.